Diana Isaacs, PharmD, and Natalie Bellini, DNP, review early MiniMed Vivera data on optional meal announcements and twiist's new type 2 diabetes clearance.
News|Videos|May 5, 2026
8 Endocrinology Headlines You Missed in April 2026
Author(s)Ryan Livingston
Fact checked by: Chelsie Derman
Catch up on key clinician insights, major FDA decisions, groundbreaking trial results, and more.
Advertisement
Advertisement
April was a packed month for endocrinology, with several decisions by the
Related to this article
Retatrutide lowered A1C 2.2% vs 1.8% and cut weight 19.5%-20.9% vs 9.4% with semaglutide 2 mg at 80 weeks in adults with type 2 diabetes.
Brynn Marks, MD, MSHPEd, joins Diana Isaacs, PharmD, and Natalie Bellini, DNP, to discuss a new framework defining fully closed loop insulin delivery.
Stay updated with the latest healthcare breakthroughs, including new TRANSCEND-T2D-2 data and FDA actions.
Vanda’s oral NK-1 receptor antagonist cut any vomiting by 27% vs placebo after a single 1 mg semaglutide dose, and the company plans an sNDA submission.
The FDA updated the risankizumab label to make pretreatment TB evaluation a matter of clinical judgment across all indications, including psoriasis.
Phase 2 and 3 data show difamilast 1% ointment improved severity and itch within 1 week in adults and children with mild to moderate atopic dermatitis.
Final VALUE data show fewer drug changes with risankizumab vs other biologics over 37 months in patients with psoriasis and comorbid psoriatic arthritis.
Advertisement
Advertisement